targeted transdifferentiation of the bladder urothelium, N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) mouse model, Urothelial stem cells, urothelial and basal marker expression, KRT14 expressing stem cells, significance of EGFR inhibition with erlotinib, patients with NMIBC.
APCCC 2024 advanced prostate cancer, use of genomic classifiers and artificial intelligence tools as predictors of treatment benefit in prostate cancer patients, prostate cancer mortality,…
APCCC 2024 management of mHSPC, EMA established the Cancer Medicines Forum, androgen deprivation and continuing the ARTA, LIBERTAS study, EMBARK, DE-ESCALATE EORTC 2238 trial, intermittent…
APCCC 2024 update on the IRONMAN project, IRONMAN Executive Committee, treatment of advanced prostate cancer, Engaging Men in Patient Reported Outcomes, PROfound study, abiraterone, enzalutamide,…
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Escalation Strategies in Patients with mHSPC, Unfavourable PSA Decline, PSA progression, radiographic progression, clinical progression,…
APCCC 2024 metastatic hormone-sensitive prostate cancer (mHSPC), metachronous low-volume mHSPC, ‘total therapy’ with metastasis-directed therapy (MDT), ‘Pokemet’ approach,
APCCC 2024, Advanced Prostate Cancer, radical prostatectomy, pelvic lymph node dissection, cN1 disease, Extended pelvic lymph node dissection, RAVES trial, RADICALS-RT trial, GETUG 17 trial,…
APCCC 2024, prostate cancer, Radiation Therapy Schedules for prostate cancer, Locally Advanced Prostate Cancer, GETUG-AFU 18 trial, dose-escalated external beam radiotherapy, ultrahypofractionation, ultrahypofractionation via stereotactic…
APCCC 2024 management of metastatic hormone sensitive prostate cancer (mHSPC), synchronous high-volume mHSPC, HORRAD trial, de novo mHSPC, STAMPEDE Arm H, STOPCAP collaboration.
APCCC 2024 metastatic hormone sensitive prostate cancer (mHSPC), patients with mHSPC that should receive “total therapy”, External beam radiation, abiraterone, enzalutamide, apalutamide, darolutamide.
APCCC 2024 how to manage patients with synchronous low-volume mHSPC, combination systemic therapy plus local treatment of the primary for synchronous low-volume mHSPC, ADT alone…
